Varun Monga

MBBS

Medical oncologist
Movie buff and passionate sarcoma researcher

About me

Dr. Varun Monga is a medical oncologist who cares for patients with bone and soft tissue growths, including tumors in connective tissue, in the digestive tract, and in joints.

As part of UCSF's early-phase experimental therapeutics program, Monga enrolls and treats patients in phase 1 clinical trials (studies evaluating promising treatments with human volunteers). He collaborates with basic scientists and other researchers to study new cancer treatment combinations. He focuses particularly on developing targeted therapies and immunotherapies to treat sarcomas.

Monga earned his medical degree at Rajiv Gandhi Medical College in India. He completed a residency in internal medicine at Rosalind Franklin University of Medicine and Science, where he served as chief resident. He completed a fellowship in hematology and medical oncology at the University of Iowa. Before joining UCSF, he worked at the University of Iowa, caring for patients and conducting research on tumors of the nervous system and sarcomas.

  • Education

    Rajiv Gandhi Medical College, MBBS, 2006

  • Residencies

    Rosalind Franklin University of Medicine and Science, Internal Medicine, 2010

  • Fellowships

    University of Iowa, Hematology and Medical Oncology, 2016

  • Academic Title

    Associate Professor

Cancer care requires a personalized, team-based approach. Collaboration among researchers, providers and patients is crucial to advancing treatment.

Conditions I specialize in

Where I see patients (2)

    My reviews

    4.9

    Overall Experience
    145 Ratings
    About our process
    Dec 19, 2024
    Down to earth and very informative
    Dec 15, 2024
    Dr Monga is very thorough in his explanations and also very forthright about probable outcomes. His openess and honesty is appreciated.
    Nov 22, 2024
    Excellent visit
    Oct 18, 2024
    Excellent treatment
    Oct 08, 2024
    Great experience
    Sep 30, 2024
    Hopefully standard of care will work for anyone I would consider referring vs clinical trials
    Sep 18, 2024
    Definitely refer Dr Monga to others.
    Aug 21, 2024
    The caregiver was very helpful
    Aug 14, 2024
    Dr Monga is an outstanding, exemplary caregiver who explains the situation lucidly and patiently. We never felt like he was in any kind of hurry, and felt a strong empathy and sympathy from him.
    Jun 29, 2024
    Everything was fine
    Jun 15, 2024
    All very well
    May 27, 2024
    Excellent experience
    May 11, 2024
    Dr. Monga is the best.
    Apr 30, 2024
    Dr Monga is very nice and I like him a lot
    Apr 14, 2024
    Dr Monga's information was clear and appreciate his holding of my interest over filling trials and providing specifics on pros and cons of each treatment option.
    Mar 29, 2024
    I could not have asked for more
    Mar 26, 2024
    Varun Monga went ABOVE and BEYOND yesterday in the hours he spent with me
    Mar 13, 2024
    I am incredibly grateful for Dr Monga
    Mar 11, 2024
    Doctor was very thorough, empathetic and provided information with my interest in mine.
    Jan 06, 2024
    We are so lucky to have Dr. Monga at UCSF
    Dec 12, 2023
    Excellent
    Oct 06, 2023
    Dr Munga is excellent
    Jun 23, 2023
    All exvellent
    Jun 21, 2023
    Dr. Monga explained everything from past scans and meds to some new options.

    Selected research

    See all research
    Decorative Caduceus

    A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects with Solid T...

    Adverse effects

    Recruiting

    Decorative Caduceus

    Intratumoral Vusolimogene Oderparepvec (VO) in Combination with Pembrolizumab for Angiosarcoma

    Safety and tolerability will be reported as the percentage of the first 6 participants (the safety-lead in participants) who received at least one dose of study treatment with any reported treatment-emergent adverse events (TEAEs)...

    Recruiting

    Decorative Caduceus

    Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Includi...

    Adverse events will be assessed and severity assigned by using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.

    Recruiting

    Decorative Caduceus

    Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients Wit...

    Will be compared between the treatment arms (doxorubicin + pembrolizumab versus [vs] doxorubicin alone). The comparison of PFS between treatment arms will be done using a stratified (on Eastern Cooperative Oncology group performan...

    Recruiting

    Contact me

    Share